Cisplatin-Induced Peripheral Neuropathy: An Observational Descriptive Study

Anjol Kurian; Bittu Babu; Benson Punnoose; Chinju Susan Chacko; Mallikarjuna Rao; Sharad Chand; Vinay B C; Nandakumar U P

Anjol Kurian ⁽¹⁾ , Bittu Babu ⁽²⁾ , Benson Punnoose ⁽³⁾ , Chinju Susan Chacko ⁽⁴⁾ , Mallikarjuna Rao ⁽⁵⁾ , Sharad Chand ⁽⁶⁾ , Vinay B C ⁽⁷⁾ , Nandakumar U P ⁽⁸⁾

(1) Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru - 575018, Karnataka, India, India ,

(2) Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru - 575018, Karnataka, India, India ,

(3) Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru - 575018, Karnataka, India, India ,

(4) Department of Pharmacy Practice, College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore, India, India ,

(5) Department of Oncology, Justice K.S. Hegde Charitable Hospital, Nitte (Deemed to be University), Mangaluru - 575018, Karnataka, India, India ,

(6) Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru - 575018, Karnataka, India, India ,

(7) Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru - 575018, Karnataka, India, India ,

(8) Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru - 575018, Karnataka, India, India

Issue
Vol. 11 No. 3 (2020): Volume 11 Issue 3

Keywords:

Cisplatin, peripheral neuropathy, adverse drug reaction, patient safety

PDF LaTeX HTML ePUB

Abstract

Peripheral neurotoxicity is a major adverse effect of cisplatin chemotherapy. A prospective observational study was conducted among 200 cancer patients who received cisplatin between October 2017 and March 2018 to evaluate the occurrence, causality and severity of cisplatin induced peripheral neuropathy. A suitable data collection form was used to record patient information required for the study. Peripheral neuropathy was assessed using the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE). As per the results, 19 (9.5%) patients developed peripheral neuropathy after receiving cisplatin therapy. Peripheral neuropathy was reported higher in males (84.2%) compared to females (15.7%) and more within the age group of 58-65 years (38.6%). Most of the patients developed Grade I neuropathy (84.2%), followed by Grade II neuropathy (15.7%). The study concluded that the severity of peripheral neuropathy increases with higher cumulative doses of cisplatin.